Table of Content

1. Key Insights

2. Executive Summary of Obese patients with Schizophrenia

3. Competitive Intelligence Analysis for Obese patients with Schizophrenia

4. Obese patients with Schizophrenia : Market Overview at a Glance
4.1. Obese patients with Schizophrenia Total Market Share (%) Distribution in 2017
4.2. Obese patients with Schizophrenia Total Market Share (%) Distribution in 2030

5. Obese patients with Schizophrenia : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Obese patients with Schizophrenia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Obese patients with Schizophrenia Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Obese patients with Schizophrenia Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Obese patients with Schizophrenia Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Obese patients with Schizophrenia Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Obese patients with Schizophrenia Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Obese patients with Schizophrenia Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Obese patients with Schizophrenia Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Obese patients with Schizophrenia Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Obese patients with Schizophrenia Treatment and Management
8.2. Obese patients with Schizophrenia Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Obese patients with Schizophrenia Treatment

11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report

12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report

13. Obese patients with Schizophrenia : Seven Major Market Analysis
13.1. Key Findings
13.2. Obese patients with Schizophrenia Market Size in 7MM
13.3. Obese patients with Schizophrenia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Obese patients with Schizophrenia Total Market Size in the United States
15.1.2. Obese patients with Schizophrenia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Obese patients with Schizophrenia Total Market Size in Germany
15.3.2. Obese patients with Schizophrenia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Obese patients with Schizophrenia Total Market Size in France
15.4.2. Obese patients with Schizophrenia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Obese patients with Schizophrenia Total Market Size in Italy
15.5.2. Obese patients with Schizophrenia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Obese patients with Schizophrenia Total Market Size in Spain
15.6.2. Obese patients with Schizophrenia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Obese patients with Schizophrenia Total Market Size in the United Kingdom
15.7.2. Obese patients with Schizophrenia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Obese patients with Schizophrenia Total Market Size in Japan
15.8.3. Obese patients with Schizophrenia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Obese patients with Schizophrenia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.



List of Figures


Figure 1: 7MM Obese patients with Schizophrenia Epidemiology (2017-2030)
Figure 2: 7MM Obese patients with Schizophrenia Diagnosed and Treatable Cases (2017-2030)
Figure 3: Obese patients with Schizophrenia Epidemiology in the United States (2017-2030)
Figure 4: Obese patients with Schizophrenia Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5: Obese patients with Schizophrenia Epidemiology in Germany (2017-2030)
Figure 6: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7: Obese patients with Schizophrenia Epidemiology in France (2017-2030)
Figure 8: Obese patients with Schizophrenia Diagnosed and Treatable Cases in France (2017-2030)
Figure 9: Obese patients with Schizophrenia Epidemiology in Italy (2017-2030)
Figure 10: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11: Obese patients with Schizophrenia Epidemiology in Spain (2017-2030)
Figure 12: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13: Obese patients with Schizophrenia Epidemiology in the UK (2017-2030)
Figure 14: Obese patients with Schizophrenia Diagnosed and Treatable Cases in the UK (2017-2030)
Figure 15: Obese patients with Schizophrenia Epidemiology in Japan (2017-2030)
Figure 16: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
Figure 20: Region-wise Market Size in USD, Million (2017-2030)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
Figure 22: United States Market Size in USD, Million (2017-2030)
Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
Figure 24: Germany Market Size in USD, Million (2017-2030)
Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
Figure 26: France Market Size in USD, Million (2017-2030)
Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
Figure 28: Italy Market Size in USD, Million (2017-2030)
Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
Figure 30: Spain Market Size in USD, Million (2017-2030)
Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Figure 34: Japan Market Size in USD, Million (2017-2030)
Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)
*The list of figures is not exhaustive; the final content may vary.


List of Tables


Table 1: 7MM Obese patients with Schizophrenia Epidemiology (2017-2030)
Table 2: 7MM Obese patients with Schizophrenia Diagnosed and Treatable Cases (2017-2030)
Table 3: Obese patients with Schizophrenia Epidemiology in the United States (2017-2030)
Table 4: Obese patients with Schizophrenia Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5: Obese patients with Schizophrenia Epidemiology in Germany (2017-2030)
Table 6: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7: Obese patients with Schizophrenia Epidemiology in France (2017-2030)
Table 8: Obese patients with Schizophrenia Diagnosed and Treatable Cases in France (2017-2030)
Table 9: Obese patients with Schizophrenia Epidemiology in Italy (2017-2030)
Table 10: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11: Obese patients with Schizophrenia Epidemiology in Spain (2017-2030)
Table 12: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13: Obese patients with Schizophrenia Epidemiology in the UK (2017-2030)
Table 14: Obese patients with Schizophrenia Diagnosed and Treatable Cases in the UK (2017-2030)
Table 15: Obese patients with Schizophrenia Epidemiology in Japan (2017-2030)
Table 16: Obese patients with Schizophrenia Diagnosed and Treatable Cases in Japan (2017-2030)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
Table 20: Region-wise Market Size in USD, Million (2017-2030)
Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
Table 22: United States Market Size in USD, Million (2017-2030)
Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
Table 24: Germany Market Size in USD, Million (2017-2030)
Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
Table 26: France Market Size in USD, Million (2017-2030)
Table 27: France Market Size by Therapy in USD, Million (2017-2030)
Table 28: Italy Market Size in USD, Million (2017-2030)
Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
Table 30: Spain Market Size in USD, Million (2017-2030)
Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
Table 32: United Kingdom Market Size in USD, Million (2017-2030)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Table 34: Japan Market Size in USD, Million (2017-2030)
Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)
*The list of tables is not exhaustive; the final content may vary